Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Trial Profile

Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs HuMax TF ADC (Primary)
  • Indications Bladder cancer; Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Genmab
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2017.
    • 23 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top